InMed Pharmaceuticals Inc (INM)

[Aladdin80]

Good points noted. My concern is that EB itself is categorized as a rare disorder only affecting something like 1 out of 20,000. That said the market cap for any EB treatment/cure is relatively small when compared to drugs catered to a much larger target market. Perhaps they (Abeona and IMLFF) have some potential within the same small space, but I'd be more confident if IMLFF's INM-750 was much further along with respect to clin trials. I personally think that it won't be the drugs (INM-750) or others in their pipeline that will make this a banner company, but finding a way to monetize the bioinformatics technology. That's why I'm personally intrigued by them.